{"success":true,"data":{"pressRelease":{"id":"39837","rtpr_id":"nBw7YS0G5a","ticker":"TLSI","exchange":"NASDAQ","all_tickers":["TLSI"],"title":"Securities Fraud Investigation Into TriSalus Life Sciences Inc. (TLSI) Announced – Shareholders Who Lost Money Urged To Contact The Law Offices of Frank R. Cruz","author":"Business Wire","published_at":"2026-05-19T19:47:00.171Z","article_body":"Securities Fraud Investigation Into TriSalus Life Sciences Inc. (TLSI)\nAnnounced – Shareholders Who Lost Money Urged To Contact The Law Offices of\nFrank R. Cruz\n\nThe Law Offices of Frank R. Cruz\n(https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Fwww.frankcruzlaw.com%2F&esheet=54538800&newsitemid=20260519032137&lan=en-US&anchor=The+Law+Offices+of+Frank+R.+Cruz&index=1&md5=3ef11fbb481c873bb7af4bb883a85fcf)\nannounces an investigation of TriSalus Life Sciences Inc. (“TriSalus” or\nthe “Company”) (NASDAQ: TLSI\n(https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Ffinance.yahoo.com%2Fquote%2Ftlsi&esheet=54538800&newsitemid=20260519032137&lan=en-US&anchor=TLSI&index=2&md5=20a7305c4bf5e6c09a952f1800e0e2fa)\n) on behalf of investors concerning the Company’s possible violations of\nfederal securities laws.\n\nIF YOU ARE AN INVESTOR WHO LOST MONEY ON TRISALUS LIFE SCIENCES INC. (TLSI),\nCLICK HERE\n(https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Fwww.frankcruzlaw.com%2Fcases%2Ftrisalus-life-sciences-inc%2F&esheet=54538800&newsitemid=20260519032137&lan=en-US&anchor=HERE&index=3&md5=7bc5f133c58501b38292d51f3894745c)\nTO INQUIRE ABOUT POTENTIALLY PURSUING A CLAIM TO RECOVER YOUR LOSS.\n\nWhat Is The Investigation About?\n\nOn May 12, 2026, TriSalus reported first quarter results, including revenue of\n$8.90M, a decline of 2.92% year over year. The Company further announced a cut\nto full year revenue guidance to $54 million to $57, a cut of $5.5 million at\nthe midpoint compared to prior guidance.\n\nIn the accompanying earnings call, management explained “the driver of this\nrevision includes both the lower Q1 revenues from the commercial expansion and\nthe delayed FDA clearance timing for TriNav Advance.” Management further\nstated FDA clearance for TriNav Advance “is now running approximately 5\nmonths past the 30-day MDUFA review goal.”\n\nOn this, TriSalus’s stock price fell $1.89 per share, or 41.56%, to close at\n$2.67 on May 13, 2026, thereby injuring investors.\n\nContact Us To Participate or Learn More:\n\nIf you purchased TriSalus securities, have information or would like to learn\nmore about these claims, or have any questions concerning this announcement or\nyour rights or interests with respect to these matters, please contact us:\n\nThe Law Offices of Frank R. Cruz,\n\n2121 Avenue of the Stars, Suite 800,\n\nCentury City, California 90067\n\nCall us at: 310-914-5007\n\nEmail us at: info@frankcruzlaw.com \n(mailto:info@frankcruzlaw.com) \nVisit our website at: www.frankcruzlaw.com\n(https://cts.businesswire.com/ct/CT?id=smartlink&url=http%3A%2F%2Fwww.frankcruzlaw.com&esheet=54538800&newsitemid=20260519032137&lan=en-US&anchor=www.frankcruzlaw.com&index=4&md5=947df6098ee5733993c63688de217fe9)\n.\n\nFollow us for updates on Twitter at twitter.com/FRC_LAW\n(https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Ftwitter.com%2FFRC_LAW&esheet=54538800&newsitemid=20260519032137&lan=en-US&anchor=twitter.com%2FFRC_LAW&index=5&md5=468db0956d4fca8ac3598f9c61dfe6af)\n.\n\nIf you inquire by email, please include your mailing address, telephone\nnumber, and number of shares purchased.\n\nThis press release may be considered Attorney Advertising in some\njurisdictions under the applicable law and ethical rules.\n\n\n\nView source version on businesswire.com:\nhttps://www.businesswire.com/news/home/20260519032137/en/\n(https://www.businesswire.com/news/home/20260519032137/en/)\n\nContact Us: \n\nThe Law Offices of Frank R. Cruz, Los Angeles\n\nFrank R. Cruz\n\n310-914-5007\n\nfcruz@frankcruzlaw.com \n(mailto:fcruz@frankcruzlaw.com) \nwww.frankcruzlaw.com\n(https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Fwww.frankcruzlaw.com&esheet=54538800&newsitemid=20260519032137&lan=en-US&anchor=www.frankcruzlaw.com&index=6&md5=48a4bb5d8dd0bb182bc83e41ac159340)\n\n\nCopyright Business Wire 2026","article_body_html":"","raw_payload":{"data":{"id":"nBw7YS0G5a","title":"Securities Fraud Investigation Into TriSalus Life Sciences Inc. (TLSI) Announced – Shareholders Who Lost Money Urged To Contact The Law Offices of Frank R. Cruz","author":"Business Wire","ticker":"TLSI","created":"2026-05-19T19:47:00.171Z","tickers":["TLSI"],"exchange":"NASDAQ","article_body":"Securities Fraud Investigation Into TriSalus Life Sciences Inc. (TLSI)\nAnnounced – Shareholders Who Lost Money Urged To Contact The Law Offices of\nFrank R. Cruz\n\nThe Law Offices of Frank R. Cruz\n(https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Fwww.frankcruzlaw.com%2F&esheet=54538800&newsitemid=20260519032137&lan=en-US&anchor=The+Law+Offices+of+Frank+R.+Cruz&index=1&md5=3ef11fbb481c873bb7af4bb883a85fcf)\nannounces an investigation of TriSalus Life Sciences Inc. (“TriSalus” or\nthe “Company”) (NASDAQ: TLSI\n(https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Ffinance.yahoo.com%2Fquote%2Ftlsi&esheet=54538800&newsitemid=20260519032137&lan=en-US&anchor=TLSI&index=2&md5=20a7305c4bf5e6c09a952f1800e0e2fa)\n) on behalf of investors concerning the Company’s possible violations of\nfederal securities laws.\n\nIF YOU ARE AN INVESTOR WHO LOST MONEY ON TRISALUS LIFE SCIENCES INC. (TLSI),\nCLICK HERE\n(https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Fwww.frankcruzlaw.com%2Fcases%2Ftrisalus-life-sciences-inc%2F&esheet=54538800&newsitemid=20260519032137&lan=en-US&anchor=HERE&index=3&md5=7bc5f133c58501b38292d51f3894745c)\nTO INQUIRE ABOUT POTENTIALLY PURSUING A CLAIM TO RECOVER YOUR LOSS.\n\nWhat Is The Investigation About?\n\nOn May 12, 2026, TriSalus reported first quarter results, including revenue of\n$8.90M, a decline of 2.92% year over year. The Company further announced a cut\nto full year revenue guidance to $54 million to $57, a cut of $5.5 million at\nthe midpoint compared to prior guidance.\n\nIn the accompanying earnings call, management explained “the driver of this\nrevision includes both the lower Q1 revenues from the commercial expansion and\nthe delayed FDA clearance timing for TriNav Advance.” Management further\nstated FDA clearance for TriNav Advance “is now running approximately 5\nmonths past the 30-day MDUFA review goal.”\n\nOn this, TriSalus’s stock price fell $1.89 per share, or 41.56%, to close at\n$2.67 on May 13, 2026, thereby injuring investors.\n\nContact Us To Participate or Learn More:\n\nIf you purchased TriSalus securities, have information or would like to learn\nmore about these claims, or have any questions concerning this announcement or\nyour rights or interests with respect to these matters, please contact us:\n\nThe Law Offices of Frank R. Cruz,\n\n2121 Avenue of the Stars, Suite 800,\n\nCentury City, California 90067\n\nCall us at: 310-914-5007\n\nEmail us at: info@frankcruzlaw.com \n(mailto:info@frankcruzlaw.com) \nVisit our website at: www.frankcruzlaw.com\n(https://cts.businesswire.com/ct/CT?id=smartlink&url=http%3A%2F%2Fwww.frankcruzlaw.com&esheet=54538800&newsitemid=20260519032137&lan=en-US&anchor=www.frankcruzlaw.com&index=4&md5=947df6098ee5733993c63688de217fe9)\n.\n\nFollow us for updates on Twitter at twitter.com/FRC_LAW\n(https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Ftwitter.com%2FFRC_LAW&esheet=54538800&newsitemid=20260519032137&lan=en-US&anchor=twitter.com%2FFRC_LAW&index=5&md5=468db0956d4fca8ac3598f9c61dfe6af)\n.\n\nIf you inquire by email, please include your mailing address, telephone\nnumber, and number of shares purchased.\n\nThis press release may be considered Attorney Advertising in some\njurisdictions under the applicable law and ethical rules.\n\n\n\nView source version on businesswire.com:\nhttps://www.businesswire.com/news/home/20260519032137/en/\n(https://www.businesswire.com/news/home/20260519032137/en/)\n\nContact Us: \n\nThe Law Offices of Frank R. Cruz, Los Angeles\n\nFrank R. Cruz\n\n310-914-5007\n\nfcruz@frankcruzlaw.com \n(mailto:fcruz@frankcruzlaw.com) \nwww.frankcruzlaw.com\n(https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Fwww.frankcruzlaw.com&esheet=54538800&newsitemid=20260519032137&lan=en-US&anchor=www.frankcruzlaw.com&index=6&md5=48a4bb5d8dd0bb182bc83e41ac159340)\n\n\nCopyright Business Wire 2026"},"type":"article","timestamp":"2026-05-19T19:47:00.192810791Z","server_sent_at_ms":1779220020192},"received_at":"2026-05-19T19:47:00.257Z","source_url":"https://www.businesswire.com/news/home/20260519032137/en/"},"analysis":{"id":"29277","press_release_id":"39837","analysis_json":{"industry":{"label":"Biotechnology","sector":"Health Care"},"redFlags":[],"eventType":"legal_litigation","narrative":"The Law Offices of Frank R. Cruz announced a securities fraud investigation into TriSalus Life Sciences (TLSI) on behalf of investors.\n\nThe investigation follows TriSalus's Q1 earnings report, which showed a 2.92% revenue decline and a significant cut to full-year guidance due to delayed FDA clearance for its TriNav Advance device.\n\nTriSalus shares fell 41.56% to $2.67 following the earnings release, prompting the law firm to solicit shareholders who lost money to contact them regarding potential claims.","sentiment":"neutral","agentHooks":{"shouldPost":false,"suggestedAngle":"Plaintiff-firm solicitation -- suppress."},"keyFigures":{"revenue":8900000,"guidance":"Full year revenue guidance cut to $54 million to $57 million (midpoint cut of $5.5 million)","revenueYoy":"-2.92%","customDimensions":{"closing_price":"$2.67","stock_price_drop":"$1.89","stock_price_drop_pct":"41.56%"}},"quotedText":"the driver of this revision includes both the lower Q1 revenues from the commercial expansion and the delayed FDA clearance timing for TriNav Advance","namedEntities":{"people":[{"name":"Frank R. Cruz","role":"Attorney / Law Firm Principal"}],"products":["TriNav Advance"],"companies":[{"name":"TriSalus Life Sciences Inc.","ticker":"TLSI","relationship":"target of investigation"},{"name":"The Law Offices of Frank R. Cruz","relationship":"plaintiff law firm"}],"dollarAmounts":[{"amount":"$8.90M","context":"Q1 2026 revenue"},{"amount":"$54 million to $57 million","context":"updated full year revenue guidance range"},{"amount":"$5.5 million","context":"midpoint guidance cut"},{"amount":"$1.89","context":"stock price drop per share"},{"amount":"$2.67","context":"closing stock price on May 13, 2026"}]},"materialImpact":{"score":1,"reasoning":"This is a plaintiff law-firm solicitation issued by The Law Offices of Frank R. Cruz. It is not an issuer disclosure, nor does it announce a certified class or settlement. Per guardrails, such solicitations are scored as low-impact noise."},"tickerRelevance":{"others":[],"primary":"TLSI"},"globalImportance":15,"audienceRelevance":10,"eventTypeSecondary":[],"importanceComponents":{"tickerTier":"small-cap","eventGravity":"law-firm-solicitation","issuerAuthored":false,"underlyingEvent":"earnings_miss_and_guidance_cut"}},"event_type":"legal_litigation","event_type_secondary":null,"sentiment":"neutral","material_impact_score":1,"narrative":"The Law Offices of Frank R. Cruz announced a securities fraud investigation into TriSalus Life Sciences (TLSI) on behalf of investors.\n\nThe investigation follows TriSalus's Q1 earnings report, which showed a 2.92% revenue decline and a significant cut to full-year guidance due to delayed FDA clearance for its TriNav Advance device.\n\nTriSalus shares fell 41.56% to $2.67 following the earnings release, prompting the law firm to solicit shareholders who lost money to contact them regarding potential claims.","key_figures":{"revenue":8900000,"guidance":"Full year revenue guidance cut to $54 million to $57 million (midpoint cut of $5.5 million)","revenueYoy":"-2.92%","customDimensions":{"closing_price":"$2.67","stock_price_drop":"$1.89","stock_price_drop_pct":"41.56%"}},"named_entities":{"people":[{"name":"Frank R. Cruz","role":"Attorney / Law Firm Principal"}],"products":["TriNav Advance"],"companies":[{"name":"TriSalus Life Sciences Inc.","ticker":"TLSI","relationship":"target of investigation"},{"name":"The Law Offices of Frank R. Cruz","relationship":"plaintiff law firm"}],"dollarAmounts":[{"amount":"$8.90M","context":"Q1 2026 revenue"},{"amount":"$54 million to $57 million","context":"updated full year revenue guidance range"},{"amount":"$5.5 million","context":"midpoint guidance cut"},{"amount":"$1.89","context":"stock price drop per share"},{"amount":"$2.67","context":"closing stock price on May 13, 2026"}]},"model_name":"qwen3_6_27b_awq","prompt_hash":"sha256:727b4b9429a443af","schema_hash":"sha256:05005c02d9cffac9","created_at":"2026-05-19T19:47:13.903Z","global_importance":15,"audience_relevance":10,"importance_components":{"tickerTier":"small-cap","eventGravity":"law-firm-solicitation","issuerAuthored":false,"underlyingEvent":"earnings_miss_and_guidance_cut"}},"durationMs":13634,"modelName":"george-droid-qwen-72b"}}